GLYCOERA AG


Associated tags: Infection, Neurology, Therapy, Biotechnology, Sofinnova, Momenta, Johnson & Johnson, Fine chemical, CHF, Engineering, Degenerative disease, Pharmaceutical industry, Research, Patient, Membrane protein, Allergy, Novartis, Pharmacology, Doctor of Philosophy

Locations: SWITZERLAND, MASSACHUSETTS

GlycoEra AG Announces New Investor, Appoints Industry Veteran Greg Fralish as Chief Business Officer

Retrieved on: 
Friday, January 5, 2024
Regeneron Pharmaceuticals, Science, Therapy, CBO, Novo Nordisk, JW, BMS, Takeda, Patient, Bristol Myers Squibb, Corporation, Pharmaceutical industry

GlycoEra also announced the addition of industry veteran Greg Fralish, Ph.D., as Chief Business Officer to expand and strengthen its leadership team.

Key Points: 
  • GlycoEra also announced the addition of industry veteran Greg Fralish, Ph.D., as Chief Business Officer to expand and strengthen its leadership team.
  • "Adding BMS as an investor further validates the depth and breadth of our platform for creating transformative therapies," said Ganesh Kaundinya, Ph.D., Chief Executive Officer of GlycoEra.
  • Previously, Dr. Fralish honed his skills as bluebird bio's Vice President of Oncology Corporate Development and Takeda's Head of Oncology Business Development.
  • "I am thrilled to join GlycoEra at this critical moment in the Company's growth," said Dr. Fralish.

GlycoEra AG Expands Board of Directors and Appoints Santiago Arroyo, MD to its Board of Directors as an independent board member

Retrieved on: 
Tuesday, May 2, 2023
Momenta, Therapy, Pfizer, Medical college, Clifton Springs Hospital & Clinic, Biotechnology, Bristol Myers Squibb, Bicycle, Associate, Universidad, Acquisition, MD, Patient, Medical College of Wisconsin, Knowledge, Johnson & Johnson, Johns Hopkins School of Medicine, Pharmaceutical industry, Management, Lundbeck

Dr. Arroyo is a tenured pharmaceutical executive who has deep expertise in strategy and leading the clinical development of therapeutics across multiple disease areas.

Key Points: 
  • Dr. Arroyo is a tenured pharmaceutical executive who has deep expertise in strategy and leading the clinical development of therapeutics across multiple disease areas.
  • Prior to joining Bicycle, Dr. Arroyo held the Chief Medical Officer position at Momenta Pharmaceuticals, leading the company's clinical development programs until Momenta's acquisition by Johnson & Johnson.
  • We look forward to working closely with him and benefiting from his strategic insights and deep leadership and operational expertise."
  • I look forward to working together with the highly experienced Board and leadership team to build GlycoEra into a leading protein degradation company" said Dr. Santiago Arroyo.

GlycoEra AG Expands Board of Directors and Appoints Georges Gemayel, Ph.D., as Chair

Retrieved on: 
Tuesday, July 12, 2022
Genzyme, Biotechnology, Membrane protein, Society, Trustees of Princeton University, National Science Advisory Board for Biosecurity, Director, Doctor of Philosophy, Supervisory board, Princeton University, Infection, Pharmacology, Novartis, Saint Joseph University, Therapy, CEO, Pharmacy, China Biologic Products, Degenerative disease, DRS, Neurology, Board, Allergan, Corporation, Johnson & Johnson, Engineering, University of Pennsylvania Health System, Sofinnova, CHF, Department, Growth, Paris-Sud University, GlaxoSmithKline, Acquisition, Multimedia, SA, Central Waqf Council, Chair, Actelion, Molecular biology, Board of directors, Allergy, Management, Pharmaceutical industry, Prosensa, Takeda, Parmar

SCHLIEREN, Switzerland and BOSTON, July 12, 2022 /PRNewswire/ -- GlycoEra AG announced today key appointments of biotech industry leaders to its Board of Directors, including Georges Gemayel, Ph.D., as Chair, as well as Philippe Dro, Ph.D., M.B.A., and Kush Parmar, M.D., Ph.D. Dr. Gemayel is an industry veteran with more than 30 years' experience including global management, executive positions and a range of board appointments. Dr. Dro is Chairman of the Board and Chief Executive Officer at Luciole Medical and has deep experience in biotech business strategy at various emerging biotechnology and medtech companies. Dr. Parmar is a physician-scientist and Managing Partner at 5AM Ventures, where he is focused on building next-generation life science companies.

Key Points: 
  • "Georges' international biopharmaceutical leadership experience and track record of developing successful medicines will prove invaluable as we build a high-value pipeline of medicines.
  • In addition, both Philippe and Kush bring strategic, business and company building expertise to help guide our trajectory of growth."
  • He was CEO and member of the Supervisory Board at GlycoVaxyn AG prior to its acquisition by GlaxoSmithKline.
  • GlycoEra AG is a biotechnology company building a high-value pipeline of medicines based on deep expertise in glycobiology and protein degradation.

GlycoEra AG Announces Appointment of Tanmoy Ganguly, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, June 16, 2022
Therapy, Drug development, A-DNA, Inflammation, CEO, Momenta, Takeda Oncology, Biotechnology, Leadership, Research, Sofinnova, Engineering, Growth, Degenerative disease, Disease, Protein, Membrane protein, Pharmacology, Patient, Autoimmunity, Multimedia, CHF, Fine chemical, Management

SCHLIEREN, Switzerland and BOSTON, June 16, 2022 /PRNewswire/ -- GlycoEra AG today announced the appointment of Tanmoy Ganguly, Ph.D., as Chief Scientific Officer. Dr. Ganguly brings nearly 25 years of experience in biopharmaceutical research and development across a variety of therapeutic areas including autoimmune diseases, inflammation, and oncology, among others. He will lead GlycoEra's efforts to develop novel therapeutics targeting degradation of circulating and membrane proteins that cause disease, using the company's proprietary CustomGlycan platform.

Key Points: 
  • SCHLIEREN, Switzerland and BOSTON, June 16, 2022 /PRNewswire/ -- GlycoEra AG today announced the appointment of Tanmoy Ganguly, Ph.D., as Chief Scientific Officer.
  • GlycoEra announced the appointment of Dr. Kaundinya as President and CEO in May 2022.
  • The addition of Dr. Kaundinya and Dr. Ganguly strengthens a leadership team comprised of seasoned biotechnology executives, including Amir Faridmoayer, Ph.D., Chief Technology Officer, and Dominique Sirena, Ph.D., Chief Manufacturing Officer.
  • GlycoEra AG is a biotechnology company building a high-value pipeline of medicines based on deep expertise in glycobiology and protein degradation.

GlycoEra AG Appoints Ganesh V. Kaundinya as President and Chief Executive Officer

Retrieved on: 
Tuesday, May 3, 2022
Board, Antibody, Board of directors, COO, Allergy, CSO, Sofinnova, Biotechnology, Peptide, Glycomics, Engineering, Mylan, Johnson & Johnson, Glycoprotein, CHF, Faculty, MIT, Momenta, CSL, Therapy, Degenerative disease, Leadership, Neurology, Novartis, Massachusetts Institute of Technology, Infection, CEO, Sugar, New Senior Investment Group, Research, Carbohydrate, Biology, Multimedia, Management, Fine chemical

SCHLIEREN, Switzerland and BOSTON, May 3, 2022 /PRNewswire/ -- GlycoEra AG announced today the appointment of Ganesh V. Kaundinya, Ph.D. as President and Chief Executive Officer. Dr. Kaundinya has been a member of the GlycoEra AG Board of Directors since the company's inception in 2020, helping the team define corporate strategy and raise Series A capital of more than $49 million (CHF 45 million). Based on his deep industry expertise, Dr. Kaundinya will lead GlycoEra's efforts to build a high-value pipeline of novel therapeutics using its proprietary glycoengineering platform, known as CustomGlycan. Under his leadership, the company will broaden its footprint by establishing a presence in Boston and continuing to grow its team in Zurich.

Key Points: 
  • Seasoned biotech executive is former Founder, COO and CSO of Momenta Pharmaceuticals
    SCHLIEREN, Switzerland and BOSTON, May 3, 2022 /PRNewswire/ -- GlycoEra AG announced today the appointment of Ganesh V. Kaundinya, Ph.D. as President and Chief Executive Officer.
  • "I have been very impressed with the GlycoEra team's accomplishments and am delighted to join them to build the next stage of the company," said Dr. Kaundinya.
  • Previously, he was Founder, Chief Operating Officer and Chief Scientific Officer of Momenta Pharmaceuticals, which was acquired by Johnson & Johnson for $6.5 billion in 2020.
  • Dr. Kaundinya joins a leadership team comprised of seasoned biotechnology executives, including Amir Faridmoayer, Ph.D., Chief Technology Officer, and Dominique Sirena, Ph.D., Chief Manufacturing Officer.

GlycoEra AG Raises CHF 45 Million (US$ 49 Million) Series A Financing to Develop Novel Biologics Based on Innovative Glycoengineering Platform

Retrieved on: 
Friday, November 5, 2021
Professional Services, Health, Finance, Research, Science, Pharmaceutical, Biotechnology, CEO, Doctor of Philosophy, Technology, Veteran, Growth, Investment, Sofinnova, Lead, Board, Therapy, Glycosylation, Pharmaceutical industry, Cryptocurrency, Fine chemical, GlycoEra AG, 5AM Ventures, Roche Venture Fund, Sofinnova Partners, GLYCOERA AG, 5AM VENTURES, ROCHE VENTURE FUND, SOFINNOVA PARTNERS

GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners.

Key Points: 
  • GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners.
  • LimmaTech Biologics AG, from which GlycoEra was spun-out, also participated in this round.
  • GlycoEras innovative CustomGlycan platform unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics for a broad range of indications.
  • The Roche Venture Fund invests in early stage biotech and diagnostics companies to develop commercially successful innovative life science companies.